Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will complement commercial payload, linker and monoclonal antibodies services, enabling Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
The bioconjugation suite will be located at Syngene's commercial biologics facility in Bengaluru, India.
Syngene will offer fully integrated services for ADCs, placing it among a handful of CDMOs with full-service capabilities.
Author's summary: Syngene International expands ADC capabilities.
More News
- ‘Horrific’ violence as thousands flee Sudan's El Fasher
- How Qualcomm Can Compete With Nvidia For Datacenter AI Inference
- Lauri Markkanen first Jazz player to score 50 points since Karl Malone in win over Suns
- FLIR introduces AI-powered cameras for marine applications
- OpenAI Goes For-Profit and Microsoft Owns 27 Percent
- There’s no elephant in the alt protein room, says GFI CEO Nigel Sizer, but change takes time and money
- Major Shake-Up at U.S. Immigration and Customs Enforcement as Agency Leadership Overhauled
- 9 Black Actresses Who Went From Broadway To The Hollywood Big Screen
- OpenAI completes for-profit shift, gives Microsoft 27% stake
- Reimagining Nail Care: Turning Self-Care Into an Engine for Equity